secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0000950170-24-135207
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports RLY-2608+fulvestrant median PFS 11.4 months in 2L breast cancer; plans pivotal study in 2025
--------------------------------------------------------------------------------

- Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.
- Confirmed ORR 39% overall, 67% in kinase-mutation patients; CBR 67%; median follow-up 9.5 months.
- Low discontinuation rate (2 patients due to TRAEs); 94% median dose intensity; only 3% Grade 3 hyperglycemia.
- Cash and investments ~$840M as of Q3 2024; funds 2L pivotal study planned for 2025.
- Triplet combinations with ribociclib (ongoing) and atirmociclib (initiated) progressing; VMs study in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/0000950170-24-135207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017024135207/rlay-20241211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer